Crohn's disease future or investigational therapies

Recent studies have found that in patients refarctory to treatment with tumor necrosis factor (TNF) antagonists, subcutaneously administered maintenance doses of ustekinumab showed a significant benefit in terms of clinical response but not remission, and were efficacious during a period of 22 weeks.^[1]

Template:WikiDoc Sources